Biotechnology

A biotech firm has uncovered a self-perpetuating cycle that drives Alzheimer's from within the cell's mitochondria, and they've developed a drug to break it.

Colossal Foundation's rewilding fund offers cash and genetic tech to save seven species. But can a $250k budget tackle a $5M problem and prove its model?

A landmark study on equicenta® CTM shows it nearly triples a horse's odds of returning to performance, offering a ready-to-use solution that challenges the status quo.

A new undergraduate grant from a Dallas entrepreneur highlights a critical need: investing in the human capital that will drive the $2.4 trillion biotech boom.

Amphastar beats Q2 estimates with new drug sales, but a deeper look reveals pricing pressure, rising costs, and a high-stakes bet on its pipeline.

Biotech firm MetaVia reports progress on its obesity drug DA-1726, with patients reaching high doses. Promising early data sets the stage for a pivotal Q4 readout.

A reported net loss obscures core growth at 10x Genomics. An acquisition, key partnerships, and a blockbuster product launch signal a decisive strategic pivot.

A French biotech's breakthrough in topical mRNA delivery could turn skin into a programmable interface, disrupting dermatology and the multi-billion dollar beauty industry.

With spending up and losses widening, CG Oncology is leveraging its $1B cash reserve to push its promising bladder cancer drug toward a Q4 FDA submission.

A tech firm's $25K grant empowers a biotech startup to tackle agriculture's $100B plastic crisis with innovative, compostable seaweed materials.

Beyond the clinical data, ALX Oncology's latest update reveals a masterclass in strategic finance and leadership, positioning it for critical milestones.

With new patents and a $300M war chest, Beren Therapeutics nears an FDA decision for its NPC drug. But can its public benefit model survive the high-risk biotech gauntlet?

vTv Therapeutics is nearing a critical milestone with its oral drug for Type 1 diabetes. Can it solve a deadly problem while navigating the financial tightrope?

Facing Nasdaq pressure, Barinthus Bio advances its Clywedog merger and pivotal celiac disease trial, with key data expected in Q4 2026.

A $25k grant from a tech company to a biotech startup reveals a powerful new model for industrial transformation, targeting the hidden plastic in our food system.

A new clinical trial is testing a novel oncolytic virus, VCN-01, to break down pancreatic cancer's defenses, a key step toward a pivotal therapy.

A critical safety milestone for PepGen’s PGN-EDODM1 offers a glimmer of hope for myotonic dystrophy patients and highlights a novel strategy in a competitive field.

With the launch of its TED drug Lumvoa, Viridian Therapeutics steps into the commercial ring. But can early momentum and a deep pipeline justify the cost?

With $60M in new funding and veteran pharma execs on board, Vedanta Biosciences is set for the pivotal last leg of its Phase 3 trial for VE303.

With nearly $800M in cash, Immunovant is all-in on a single drug, IMVT-1402. Can its ambitious six-front clinical strategy justify the burn and win the race?